Medical Condition News

RSS

Maintenance of daily routines associated with reduced rate of insomnia in older adults

A study in the April 1 issue of the journal Sleep found that the maintenance of daily routines was associated with a reduced rate of insomnia and improved quality of sleep in older adults living in a retirement community.

1 Apr 2010

Orexigen Therapeutics announces submission of Contrave NDA for treatment of obesity

Orexigen® Therapeutics, Inc. announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity. The NDA is based on a substantial body of evidence gathered through the Contrave Obesity Research (COR) clinical program, which included over 4,500 patients.

1 Apr 2010

Tanda Professional Restore light therapy now made available for at-home use

During a press conference yesterday, doctors and experts unveiled a groundbreaking medical device using the healing properties of light therapy for pain management and improving mobility. For the first time ever, a licensed medical device that delivers clinical levels of light therapy only previously available in a doctor's office, has now been made available for at-home use.

1 Apr 2010

Personalized online resource to help Canadians achieve healthy weight loss

A Heart and Stroke Foundation survey of almost 2,000 Canadians found that 62% reported intentionally losing five or more pounds over the past five years but failed to keep the weight off. And 70% of those who were overweight or obese regained all or even more pounds after their weight-loss efforts.

1 Apr 2010

Substances from vegetable lamb plant show promise for treatment of osteoporosis

The "vegetable lamb" plant - once believed to bear fruit that ripened into a living baby sheep - produces substances that show promise in laboratory experiments as new treatments for osteoporosis, the bone-thinning disease. That's the conclusion of a new study in ACS' monthly Journal of Natural Products.

1 Apr 2010

Positive results from Ardea Biosciences' Phase 2b study of RDEA594 for hyperuricemia and gout

Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b monotherapy study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. In this 28-day, randomized, double-blind, placebo-controlled, dose-escalation study, 123 gout patients with hyperuricemia (serum urate levels greater than or equal to 8 mg/dL) received 200 mg once-daily (qd) RDEA594, 400 mg qd RDEA594, 600 mg qd RDEA594 or matching placebo.

1 Apr 2010

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

Genta Incorporated today announced that the Company has initiated a confirmatory Phase 2b trial of tesetaxel in patients with advanced gastric cancer. Tesetaxel is the Company's newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development.

31 Mar 2010

ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

ViroPharma Incorporated today announced that it has initiated an open-label, single-dose Phase 2 study to evaluate doses of Cinryze™ (C1 esterase inhibitor [human)] for treatment of acute angioedema attacks in children less than 12 years of age with hereditary angioedema.

31 Mar 2010

High-fructose corn syrup makes rats fat: Princeton University study questioned

"HFCS makes rats fat? I can hardly believe that Princeton sent out a press release yesterday announcing the results of this rat study. The press release says: "Rats with access to high-fructose corn syrup gained significantly more weight than those with access to table sugar, even when their overall caloric intake was the same."

31 Mar 2010

DSMB for DIGNITY trial recommends Celsion continue enrollment

Celsion Corporation announced today that after reviewing safety data from the 40mg/m2 cohort, the DIGNITY Study Drug Safety Monitoring Board (DSMB) has recommended that Celsion continue to enroll patients in the trial and that new patients be treated at a ThermoDox® dose of 50mg/m2.

31 Mar 2010

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

ArQule, Inc. today announced that ARQ 197, when used in combination with erlotinib, demonstrated a 66% improvement in median Progression-Free Survival in patients with advanced, refractory non-small cell lung cancer.

31 Mar 2010

Immigrants with mental disabilities: Reforms needed to ensure fair treatment and due process

Major reforms are needed in the nation's immigration court and detention system to ensure fair treatment and due process for immigrants with mental disabilities, according to new findings released today by Texas Appleseed, with pro bono counsel Akin Gump Strauss Hauer & Feld LLP.

31 Mar 2010

Fat-rich breakfast may help prevent metabolic syndrome, says study

The age-old maxim "Eat breakfast like a king, lunch like a prince and dinner like a pauper" may in fact be the best advice to follow to prevent metabolic syndrome, according to a new University of Alabama at Birmingham (UAB) study.

31 Mar 2010

LoJack and May Institute launch campaign to increase public awareness about autism

What does autism look like? Millions of commuters in Massachusetts will find out during April – National Autism Awareness Month – thanks to a powerful public awareness campaign that features photos and stories of children with autism as well as important information about the disorder.

31 Mar 2010

Panel of experts endorse effectiveness of Mirasol PRT System for preventing GVHD

CaridianBCT, a leading global provider of technology, products and services in the blood banking, transfusion medicine and cell therapy industries, today announced that a panel of medical and scientific experts have endorsed the effectiveness of the Mirasol® Pathogen Reduction Technology System for replacing gamma irradiation, the current standard of care for preventing transfusion-related Graft vs. Host Disease in platelet recipients.

31 Mar 2010

Indispensable role of Mindin in innate and adaptive immunity

Mindin has an indispensable role in both innate and adaptive immunity. A research group in China investigated regulation of mindin expression and the signaling pathway involved. mRNA expression of mindin was upregulated during dextran sulfate sodium induced mouse intestinal inflammation. Stimulation with CpG-ODN (a known TLR-9 ligand) induced upregulation of mindin expression in RAW 264.7 cells and significantly increased the NF-κB-luciferase activity in vitro.

31 Mar 2010

Vidazorb probiotic supplements could minimize severity of IBS symptoms

April is Irritable Bowel Syndrome (IBS) Awareness Month. IBS is a chronic condition affecting between 15 and 20 percent of all adults in the Western world. However, IBS is difficult to identify due to the numerous symptoms associated with it. Almost 40 percent of IBS sufferers report symptoms severe and frequent enough to disrupt their daily lives, making it is a serious issue—one to which Vidazorb® probiotic supplements may offer some relief.

31 Mar 2010

Feinstein Institute scientists seek sisters for lupus study

The SisSLE (Sisters of Women with Systemic Lupus Erythematosus) research study is looking for sisters: one with a diagnosis of systemic lupus erythematosus (SLE), an autoimmune disease and one (or more) who does not have lupus.

31 Mar 2010

Hepatectomy effective for treatment of caudate lobe HCC

Caudate hepatocellular carcinoma (HCC) has a poorer prognosis than HCC originating from other lobes, due to its proximity to the portal trunk and inferior vena cava, which facilitate intrahepatic and systemic spread early in the disease. Hepatic resection is considered, in principle, to be the first choice treatment. In order to improve surgical outcome, it is necessary to evaluate the potential risk factors affecting long-term survival and to establish guidelines for the appropriate use of hepatectomy for caudate lobectomy.

31 Mar 2010

Bioheart presents cutting edge therapies at 2010 Translational Regenerative Medicine Forum

Bioheart, Inc., announced today that Dr. Karl E. Groth, the Company's Chairman and CEO will speak at the 2010 Translational Regenerative Medicine Forum in Winston-Salem, North Carolina, on April 8. Dr. Groth will discuss Bioheart's cell therapies for Congestive Heart Failure.

31 Mar 2010

Medical Condition News

Maintenance of daily routines associated with reduced rate of insomnia in older adults

Orexigen Therapeutics announces submission of Contrave NDA for treatment of obesity

Tanda Professional Restore light therapy now made available for at-home use

Personalized online resource to help Canadians achieve healthy weight loss

Substances from vegetable lamb plant show promise for treatment of osteoporosis

Positive results from Ardea Biosciences' Phase 2b study of RDEA594 for hyperuricemia and gout

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

High-fructose corn syrup makes rats fat: Princeton University study questioned

DSMB for DIGNITY trial recommends Celsion continue enrollment

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

Immigrants with mental disabilities: Reforms needed to ensure fair treatment and due process

Fat-rich breakfast may help prevent metabolic syndrome, says study

LoJack and May Institute launch campaign to increase public awareness about autism

Panel of experts endorse effectiveness of Mirasol PRT System for preventing GVHD

Indispensable role of Mindin in innate and adaptive immunity

Vidazorb probiotic supplements could minimize severity of IBS symptoms

Feinstein Institute scientists seek sisters for lupus study

Hepatectomy effective for treatment of caudate lobe HCC

Bioheart presents cutting edge therapies at 2010 Translational Regenerative Medicine Forum

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News